The new generation of antidepressants

Hospital Medicine

Volumn 64, Issue 1, 2003, Pages 12-15

  Diab, Tarig ^a   Singh, Ashok N ^a  

^a LINCOLNSHIRE PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; REBOXETINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN;

AGRANULOCYTOSIS; BULIMIA; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; IMPOTENCE; INSOMNIA; LICENCE; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; META ANALYSIS; NAUSEA; NEUTROPENIA; NORADRENERGIC SYSTEM; OBSESSIVE COMPULSIVE DISORDER; RECEPTOR DOWN REGULATION; SEDATION; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SYSTEMATIC REVIEW; UNITED KINGDOM; WEIGHT GAIN; WITHDRAWAL SYNDROME; DRUG DESIGN; DRUG LEGISLATION; FORECASTING; INTOXICATION; REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG DESIGN; FORECASTING; HUMANS; LEGISLATION, DRUG; OVERDOSE;

EID: 0038312052     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2003.64.1.1837     Document Type: Conference Paper

References (24)

1. Anderson IM (1997) Lessons to be learned from meta-analysis of newer vs older antidepressants. Adv Psychiatr Treat 3: 58-63
2. Anderson IM (1998) SSRIS vs tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7(Suppl): 11-17
3. Baron BM, Ogden AM, Siegel BW et al (1988) Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 154: 125-34
4. Blier P, de Montigny C, Chaput Y (1988) Electrophysiological assessment of the effects of antidepressant treatments on the efficacy of 5-HT neurotransmission. Clin Neuropharmacol 11: S1-S10
5. Boyer WF, Feigner JP (1993) The financial implications of starting treatment with a SSRI or tricyclic antidepressant in drug naïve depressed patients. In: Jonsson B, Rosenbaum J, eds. Health Economics of Depression. Wiley, Chichester: 65-75
6. Clerc GE, Rumey P, Verdeau-Palles J (1994) A double blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. Int Clin Psychopharmacol 9: 139-43
7. Entsuah AR, Rudolph RL, Hackett D, Miska S (1996) Efficacy of venlafaxine and placebo during long term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 11: 137-45
8. Garcia-Pondo AC, Pozo JGD, Sanchez AS (2002) Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 63(2): 135-7
9. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (1999) SSRIs vs alternative antidepressants in depressive disorder. (Cochrane review). In: The Cochrane Library, issue 4. Update Software, Oxford
10. Hicks JA, Argyropoulos SV, Rich AS et al (2002) Randomised controlled study of sleep after nefazadone or paroxetine treatment in out-patients with depression. Br J Psychiatry 180: 528-35
11. Holsboer F (2001) Antidepressant drug discovery in the postgenomic era. World J Biol Psychiatry 2: 165-77
12. Jenkins R, Lewis G, Bebbington P, Brugha T, Farrell M, Gill B, Meltzer H (1997) the national psychiatric morbidity surveys of great Britain - initial findings from the initial household surveys. Psychol Med 27: 775-89
13. Kelly BD (2001) St John's Wort for depression: what is the evidence. Hosp Med 62(5): 274-6
14. Kessler RC, McGonagle KA, Zhao S et al (1994) Lifetime and 12 months prevalence of DSM-111-R Psychiatric Disorders in the United States. Results from the National Morbidity Survey. Arch Gen Psychiatry 51: 8-19
15. Martin RM, Hilton SR, Kerry S-M, Chards NM (1997) General practitioners perceptions of the tolerability of antidepressant drug; a comparison of SSRIs and TCAs. BMJ 314: 646-51
16. Murray CJL, Lopez AD (1997) Global mortality, disability and the contribution of risk factors: global burden of disease study. Lancet 349: 1436-42
17. Naranjo CA (1987) The serotonin uptake inhibitor citalopram attenuated ethanol intake. Clin Pharmacol Ther 41: 266-74
18. Singh AN (2003) Pharmacotherapy of depression. Postgraduate Doctor (in press)
19. Song F, Freemantle N, Sheldon TA et al (1993) selective serotonin re-uptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 306: 683-7
20. Stahl FM (1996) Essential Psychopharmacology. Cambridge University Press, Cambridge
21. Stimemel GL, Dophliede JA (1996) Psychotropic induced reduction in seizure thresholds. CNS Drugs 1: 37-50
22. Wagstaff AJ, Goa XL (2001) Once weekly fluoxetine. Drugs 61(15): 2221-8
23. Weissman MM, Bland RC, Canino GJ et al (1996) Crossnational epidemiology of major depression and bipolar disorder. JAMA 276: 293-9
24. Wells KB, Golding JM, Burnham MA (1988) Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry 145: 976-81